Results 141 to 150 of about 14,520 (202)

CDK4/6 inhibitors rechallenge post-progression in HR-positive HER2-negative advanced/metastatic breast cancer patients: a meta-analysis of Kaplan-Meier-reconstructed individual-level data. [PDF]

Breast Cancer Res
Veta Darkovski J, Michelon I, Gazzoni G, Mamede I, Jeong Y, Cavalcante L.   +5 more
europepmc   +1 more source

Optimizing second-line endocrine-based treatment in HR positive HER2 negative metastatic breast cancer: a comprehensive expert statement from the Gulf Cooperation Council Region. [PDF]

Front Oncol
Alshehri A, Altwairgi AK, AlTourah A, Alwbari A, Chehal A, Calaud F, Al-Hashem H, Marashi H, Elsamany S, Tirmazy SH.   +9 more
europepmc   +1 more source

Application of PI3K inhibitors in breast cancer treatment: a clinical trial landscape analysis based on clinical trial databases and registries. [PDF]

Front Oncol
Cao J, Chen Y, Song J, Li S, Tang Y, Zhang X, Zhang L, Ma L.   +7 more
europepmc   +1 more source

Missingness in Eligibility Criteria for Target Trial Emulation in EHR With Survival Outcomes. [PDF]

Stat Med
Shen J, Linn KA, Clark AS, Mamtani R, Hubbard RA.   +4 more
europepmc   +1 more source

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study. [PDF]

Curr Oncol
Seyyar M, Kalem A, Sali M, Karabuğa B, Sahin TK, Dişli AK, Türkel A, Karadurmuş B, Şahin Hafızoğlu E, Avcı N, Bilgetekin I, Köse Baytemur N, Uguztemur E, Oflazoğlu U, Gür HB, Hacıbekiroğlu İ, Akkuş AF, Topaloğlu S, Bayramgil A, Dülgar Kaya Ö, Yazıcı M, Şakalar T, Akay S, Majidova N, Guliyev M, Alan Ö, Gülcü S, Eren T, İmamoğlu Gİ, Güren AK, Köstek O, Ünlü A, Ozturk B, Aydın E, Safarov S, Doğan B, Tükenmez MA, Demir T, Şahin E, Erdemoğlu E, Keskin Uzundere F, Bütün O, Karabulut B, Uzun M, Baydaş T, Karaman E, Arak H, Ekinci F, Aykan MB, Ertürk İ, Guven DC, Deligönül A, Karaçin C, Ateş Ö, İnanç M, Yeşil H, Aksoy S, Köşeci T, Ökten İN, Yıldırım HÇ, Çabuk D.   +60 more
europepmc   +1 more source

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025. [PDF]

Curr Oncol
Jerzak KJ, Kumar A, Boileau JF, Bouganim N, Brezden-Masley C, Cao JQ, Cescon DW, Chia S, Edwards S, Joy AA, Laing K, LeVasseur N, Lupichuk S, Sehdev S, Simmons C, Webster M, Gelmon KA, Manna M, On Behalf Of Patient Advocacy Breast Cancer Canada.   +18 more
europepmc   +1 more source

CDK4/6 inhibitor rechallenge therapy in advanced breast cancer. [PDF]

Discov Oncol
Sun Y, Zhao Y, Yu X, Qi Y, Dai X.
europepmc   +1 more source

Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial. [PDF]

Nat Commun
Zhang P, Sun T, Wang Y, Li W, Tong Z, Phadke S, Feinstein T, Ma W, Guo P, Zhang M, Yue Y, Xu B.   +11 more
europepmc   +1 more source

Exploration of real-world outcomes in patients with previously treated HR+/HER2- and triple negative metastatic breast cancer. [PDF]

Sci Rep
Sadetsky N, Prince P, Latimer H, Advani P, Smith-Gaziani D, Kaufman PA, Natanzon Y, Taylor A, Nguyen L, Freemantle N.   +9 more
europepmc   +1 more source

Extracellular ATP promotes endocrine resistance in ER+ breast cancer through upregulation of PYGL. [PDF]

Cell Death Dis
Yu YQ, Yu XY, Li XF, Cheng YF, Zhou YT, Mei F, Weng L, Tian XX.   +7 more
europepmc   +1 more source